
Reveal risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguatREVEAL Risk Scores with Riociguat in CTEPH

Raymond L. Benza, Harrison W. Farber, Adaani Frost, Ekkehard Grünig, Marius M. Hoeper, Dennis Busse, Christian Meier, Sylvia Nikkho, Hossein-Ardeschir Ghofrani



 PII:
 S1053-2498(18)31381-0

 DOI:
 https://doi.org/10.1016/j.healun.2018.02.015

 Reference:
 HEALUN6718

To appear in: Journal of Heart and Lung Transplantation

Cite this article as: Raymond L. Benza, Harrison W. Farber, Adaani Frost, Ekkehard Grünig, Marius M. Hoeper, Dennis Busse, Christian Meier, Sylvia Nikkho and Hossein-Ardeschir Ghofrani, Reveal risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguatREVEAL Risk Scores with Riociguat in CTEPH, *Journal of Heart and Lung Transplantation*, doi:10.1016/j.healun.2018.02.015

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

REVEAL RISK SCORE IN PATIENTS WITH CHRONIC

THROMBOEMBOLIC PULMONARY HYPERTENSION RECEIVING

RIOCIGUAT

Raymond L. Benza, MD,^a Harrison W. Farber, MD,^b Adaani Frost, MD,^c Ekkehard Grünig, MD,^d Marius M. Hoeper, MD,^e Dennis Busse, Dipl. Stat,^f Christian Meier, MD,^g Sylvia Nikkho, MD,^h and Hossein-Ardeschir Ghofrani, MD^{i,j}

From the ^aCardiovascular Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania; ^bPulmonary Center, Boston University School of Medicine, Boston, Massachusetts; ^cHouston Methodist Hospital & Weill Cornell Medical College, Houston, Texas; ^dCenter for Pulmonary Hypertension, Thorax Clinic, University Hospital Heidelberg, Heidelberg, Germany; ^eClinic for Respiratory Medicine, Hannover Medical School, member of the German Center for Lung Research (DZL), Hannover, Germany; ^fChrestos Concept GmbH & Co. KG, Essen, Germany; ^gGlobal Medical Affairs, Bayer AG, Berlin, Germany; ^hGlobal Clinical Development, Bayer AG, Berlin, Germany; ⁱUniversity of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Giessen, Germany; and the ⁱDepartment of Medicine, Imperial College London, London, United Kingdom.

Reprint requests: Raymond L. Benza, MD, FACC, Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA 15212. Telephone: +1 412 359 3584. Fax: +1 412 359 6334. E-mail address: rbenza@wpahs.org

Running header: REVEAL Risk Scores with Riociguat in CTEPH

Target journal: Journal of Heart and Lung Transplantation

Download English Version:

https://daneshyari.com/en/article/8669173

Download Persian Version:

https://daneshyari.com/article/8669173

Daneshyari.com